IAN
ALXN

Integrated Advisors Network’s Alexion Pharmaceuticals ALXN Stock Holding History

Integrated Advisors Network’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,509
Closed -$828K – 643
2021
Q2 		$828K Sell
4,509
-768
-15% -$132K 0.06% 260
2021
Q1 		$807K Sell
5,277
-1,096
-17% -$170K 0.07% 237
2020
Q4 		$996K Sell
6,373
-1,752
-22% -$225K 0.11% 196
2020
Q3 		$930K Buy
8,125
+1,325
+19% +$143K 0.12% 183
2020
Q2 		$764K Buy
+6,800
New +$722K 0.09% 211

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Integrated Advisors Network's ALXN Position: Q3 2021 in Review

Integrated Advisors Network sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,509 shares — an estimated $828K sold.

Integrated Advisors Network first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $996K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Integrated Advisors Network reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Integrated Advisors Network sold 4,509 Alexion Pharmaceuticals shares in Q3 2021, an estimated $828K.
  • Integrated Advisors Network first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Integrated Advisors Network's Alexion Pharmaceuticals position peaked at $996K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Integrated Advisors Network's 13F filing for Q3 2021, filed 15 Nov 2021.